Current strategies to treat tuberculosis [version 1; referees: 2 approved]

Authors :: Anthony T. Podany
Susan Swindells
Author Affiliations :: <relatesTo>1</relatesTo>College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska, USA<br /><relatesTo>2</relatesTo>Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA
Source :: F1000Research. 5:F1000 Faculty Rev-2579
Publication Year :: 2016
Publisher :: London, UK: F1000 Research Limited, 2016.
Abstract: Tuberculosis (TB) has been a leading cause of death for more than a century. While effective therapies exist, treatment is long and cumbersome. TB control is complicated by the overlapping problems created by global inadequacy of public health infrastructures, the interaction of the TB and human immunodeficiency virus (HIV) epidemics, and the emergence of drug-resistant TB. After a long period of neglect, there is now significant progress in the development of novel treatment regimens for TB. Focusing on treatment for active disease, we review pathways to TB regimen development and the new and repurposed anti-TB agents in clinical development.

Subjects :: Review
Articles
Bacterial Infections
HIV Infection & AIDS: Clinical
Medical Microbiology
Pediatric Infectious Diseases
Respiratory Infections
Respiratory Pediatrics
Tuberculosis
Rifamycin
Fluoroquinolones
Clofazamine
Bedaquiline
Nitroimidazoles
Pretonamid
Delamanid
Oxazolidinones

ISSN :: 20461402
Volume :: 5
Database :: F1000Research
Journal :: F1000Research
Notes :: Editorial Note on the Review Process F1000 Faculty Reviews are commissioned from members of the prestigious F1000 Faculty and are edited as a service to readers. In order to make these reviews as comprehensive and accessible as possible, the referees provide input before publication and only the final, revised version is published. The referees who approved the final version are listed with their names and affiliations but without their reports on earlier versions (any comments will already have been addressed in the published version). The referees who approved this article are: Digby Warner, Molecular Mycobacteriology Research Unit, Institute of Infectious Disease and Molecular Medicine and Department of Pathology, University of Cape Town, Cape Town, South Africa No competing interests were disclosed. Andreas Diacon, Task Applied Science and Department of Internal Medicine, University of Stellenbosch , Cape Town, South Africa No competing interests were disclosed., , [version 1; referees: 2 approved]
Publication Type :: Academic Journal
Accession number :: edsfor.10.12688.f1000research.7403.1
Document Type :: review
Full Text :: https://doi.org/10.12688/f1000research.7403.1